Flipping Book

Dosimetric dose

(450 mg tositumomab,

5 mCi

131

I tositumomab

[35 mg])

Whole body

counts

x 3

Therapeutic dose

(450 mg tositumomab,

mCi dose of

131

I tositumomab [35 mg] to deliver

desired cGy TBD)

Treatment Regimen for

131

I Tositumomab

(Licensed in USA – no longer available)

Day 7–14

Day 0

Thyroprotection: Day -1 continuing through 14 days post-therapeutic dose

• Unlabeled predose infused

over 1 hour

• Administered mCi activity

determined by gamma counts

• Unlabeled predose infused

over 1 hour

• Dosimetric dose used to determine

individual pharmacokinetics